Health Catalyst (NASDAQ:HCAT) Price Target Lowered to $9.00 at Canaccord Genuity Group

Health Catalyst (NASDAQ:HCAT) had its price objective reduced by Canaccord Genuity Group from $10.00 to $9.00 in a research report sent to investors on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other equities research analysts also recently commented on HCAT. Wells Fargo & Company reduced their price objective on Health Catalyst from $13.00 to $10.00 and set an “overweight” rating for the company in a report on Tuesday, January 21st. Stifel Nicolaus boosted their target price on shares of Health Catalyst from $5.00 to $5.50 and gave the company a “hold” rating in a research note on Thursday. Royal Bank of Canada cut their price objective on Health Catalyst from $7.00 to $6.00 and set a “sector perform” rating for the company in a report on Thursday, February 27th. KeyCorp lowered their target price on Health Catalyst from $7.00 to $5.00 and set an “overweight” rating on the stock in a report on Wednesday, April 16th. Finally, Stephens reduced their price target on shares of Health Catalyst from $7.00 to $5.00 and set an “equal weight” rating for the company in a research report on Thursday, March 6th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $8.00.

Health Catalyst Price Performance

Shares of NASDAQ HCAT opened at $4.14 on Thursday. The company has a 50 day moving average of $4.13 and a 200 day moving average of $5.92. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. Health Catalyst has a twelve month low of $3.56 and a twelve month high of $9.24. The firm has a market cap of $290.67 million, a P/E ratio of -3.07 and a beta of 1.56.

Insider Buying and Selling

In other news, insider Linda Llewelyn sold 6,441 shares of Health Catalyst stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $5.43, for a total value of $34,974.63. Following the sale, the insider now directly owns 85,819 shares of the company’s stock, valued at approximately $465,997.17. The trade was a 6.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, General Counsel Benjamin Landry sold 13,827 shares of the stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $4.55, for a total value of $62,912.85. Following the transaction, the general counsel now directly owns 160,437 shares of the company’s stock, valued at approximately $729,988.35. The trade was a 7.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 47,588 shares of company stock valued at $217,259. Corporate insiders own 2.50% of the company’s stock.

Institutional Investors Weigh In On Health Catalyst

Large investors have recently bought and sold shares of the business. Group One Trading LLC increased its holdings in shares of Health Catalyst by 107.6% in the 4th quarter. Group One Trading LLC now owns 4,360 shares of the company’s stock worth $31,000 after buying an additional 2,260 shares during the last quarter. Two Sigma Securities LLC raised its position in Health Catalyst by 19.5% during the fourth quarter. Two Sigma Securities LLC now owns 17,510 shares of the company’s stock valued at $124,000 after purchasing an additional 2,862 shares during the period. Legato Capital Management LLC lifted its stake in shares of Health Catalyst by 3.7% in the 4th quarter. Legato Capital Management LLC now owns 87,992 shares of the company’s stock valued at $622,000 after purchasing an additional 3,171 shares during the last quarter. Quantbot Technologies LP purchased a new position in shares of Health Catalyst in the 4th quarter worth approximately $29,000. Finally, Price T Rowe Associates Inc. MD increased its position in shares of Health Catalyst by 8.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 62,443 shares of the company’s stock valued at $442,000 after purchasing an additional 4,798 shares during the last quarter. Institutional investors own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.